<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04664803</url>
  </required_header>
  <id_info>
    <org_study_id>KUP-CFC-401</org_study_id>
    <nct_id>NCT04664803</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy of Cefecin Tab. in Patients With Acute Sinusitis</brief_title>
  <acronym>CASIS</acronym>
  <official_title>A Clinical Trial to Re-confirm the Efficacy and the Safety of Cefetamet Pivoxil Formulation in Sinusitis Patients: Double Blinded, Randomized, Parallel Designed, Multi-center, Active Comparator Study (CASIS Study)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Korea United Pharm. Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Korea United Pharm. Inc.</source>
  <oversight_info>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a multi-center, double-blind, randomized, active controlled, parallel group phase 4&#xD;
      clinical trial to re-confirm the efficacy and safety of cefetamet pivoxil formulation in&#xD;
      sinusitis patients&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients with acute sinusitis were randomly assigned (1:1) to receive either cefetamet (500&#xD;
      mg twice daily, study group) or cefdinir (100 mg three times a day, control group) and&#xD;
      corresponding placebo t.i.d. or b.i.d. for 2 weeks.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <start_date type="Actual">August 31, 2015</start_date>
  <completion_date type="Actual">August 31, 2019</completion_date>
  <primary_completion_date type="Actual">June 28, 2019</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Clinical effective rate</measure>
    <time_frame>21 days</time_frame>
    <description>Percentage of patients with clinical cure and improvement on days 14 and 21</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Clinical cure rate</measure>
    <time_frame>21 days</time_frame>
    <description>Percentage of patients with clinical cure on days 14 and 21</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical effective rate</measure>
    <time_frame>14 days</time_frame>
    <description>Percentage of patients with clinical cure and improvement on days 14</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in total score of clinical signs</measure>
    <time_frame>14 days</time_frame>
    <description>Evaluation of clinical signs through nasal endoscopy; purulent secretion from sinus ostia, pain over sinuses, facial swelling</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in total score of clinical signs</measure>
    <time_frame>21 days</time_frame>
    <description>Evaluation of clinical signs through nasal endoscopy; purulent secretion from sinus ostia, pain over sinuses, facial swelling</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">284</enrollment>
  <condition>Acute Sinusitis</condition>
  <arm_group>
    <arm_group_label>Cefecin Tab.</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cefecin Tab./Placebo to Omnicef Cap.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Omnicef Cap.</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Omnicef Cap./Placebo to Cefecin Tab.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cefecin Tab.</intervention_name>
    <arm_group_label>Cefecin Tab.</arm_group_label>
    <other_name>cefetamet pivoxil</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Omnicef Cap.</intervention_name>
    <arm_group_label>Omnicef Cap.</arm_group_label>
    <other_name>cefdinir</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients diagnosed with sinusitis (accompanied with otitis media) at screening, and&#xD;
             whose first symptoms occurred within the past 3 weeks&#xD;
&#xD;
          -  Symptoms or signs of acute sinusitis persist without improvement for 10 days after&#xD;
             onset or symptoms or signs of acute sinusitis initially improve and then worsen within&#xD;
             10 days&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Those who have a history of hypersensitivity to cephalosporin, penicillin, or other&#xD;
             beta-lactam antibiotics&#xD;
&#xD;
          -  Those with a history of allergic rhinitis or other rhinitis&#xD;
&#xD;
          -  Those who have been diagnosed with sinusitis more than 3 times within a year&#xD;
&#xD;
          -  Have had or scheduled sinus surgery within 1 month&#xD;
&#xD;
          -  Creatinine Clearance &lt; 40 mL/min at screening&#xD;
&#xD;
          -  Those whose AST, ALT, and total bilirubin are more than 3 times the upper limit of&#xD;
             normal at screening&#xD;
&#xD;
          -  Cystic fibrosis patients&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>November 24, 2020</study_first_submitted>
  <study_first_submitted_qc>December 7, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 11, 2020</study_first_posted>
  <last_update_submitted>December 7, 2020</last_update_submitted>
  <last_update_submitted_qc>December 7, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 11, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sinusitis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cefdinir</mesh_term>
    <mesh_term>Cefetamet</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

